文献速递系统性红斑狼疮

不同检测方法对已确诊系统性红斑狼疮患者血清抗核抗体检测的差异

Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE.
PubMed 文献 · Ann Rheum Dis · 2018-02-09

研究对103例已确诊系统性红斑狼疮(SLE)患者的血清,用三种免疫荧光法(IFA)及ELISA、珠基多重法检测抗核抗体(ANA)。IFA试剂盒间ANA阴性频率为4.9%–22.3%,ELISA为11.7%,多重法为13.6%。作者认为已确诊SLE患者可出现ANA阴性,频率随检测试剂盒而异,并对以ANA阳性作为临床试验入选标准提出疑问。

要点

  • 已确诊SLE患者中ANA阴性并非罕见,三种IFA试剂盒间阴性频率为4.9%–22.3%。
  • ELISA和珠基多重法分别检出12例(11.7%)和14例(13.6%)ANA阴性。
  • 全部检测均阳性者与结果不一致者在既往抗双链DNA阳性频率及采血时低补体水平上存在差异。

核心结论

  • 已确诊SLE患者可出现ANA阴性,其频率因检测试剂盒而异。
  • 鉴于经过充分验证的检测方法间也存在阴性率差异,作者对是否应以ANA阳性作为临床试验入选标准提出疑问。

研究设计与样本

  • 研究检测103例已确诊SLE患者的血清,用三种免疫荧光法(IFA)测定ANA,并以ELISA和珠基多重法测定ANA。

主要发现

  • 三种IFA试剂盒的ANA阴性频率为103例中5至23例(4.9%–22.3%)。
  • ELISA检出12例(11.7%)ANA阴性,珠基多重法检出14例(13.6%)ANA阴性。
  • 全部检测均阳性的样本与检测结果不一致的样本,在既往抗双链DNA阳性频率和采血时低补体水平上存在差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The expression of antinuclear antibodies (ANA) is considered almost constant in systemic lupus erythematosus (SLE), although recent experience has suggested that many subjects with SLE considered for clinical trials are ANA negative at screening. The objective of this study is to determine whether assay variation can influence ANA detection in patients with established SLE. METHODS: Sera from 103 patients with established SLE were tested using three different immunofluorescence assays (IFA) for ANA determination. ANA determinations were also performed by an ELISA and bead-based multiplex assay. RESULTS: With IFA kits, the frequency of ANA negativity varied from 5 to 23 of 103 samples (4.9%-22.3%). The ELISA and multiplex assays showed that 12 (11.7%) and 14 (13.6%) samples were negative, respectively. Samples positive in all assays differed from those with discordant assay results in the frequency of historical anti-double-stranded DNA positivity and low complement levels at the time of blood sampling. DISCUSSION: These findings indicate that ANA negativity occurs in patients with established SLE although the frequency varies depending on the assay kit. Given the range of negativity with well-validated assays, these findings raise questions about whether ANA positivity should be employed to determine eligibility for clinical trials.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Pisetsky DS, Spencer DM, Lipsky PE, et al. Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE. Ann Rheum Dis. 2018. PMID: 29440000. doi:10.1136/annrheumdis-2017-212599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。